Novo Integrated Sciences’ subsidiary, Novo Healthnet Limited, and EK-Tech Solutions Announce Joint Venture for Enhanced Telehealth Platform
2021年10月14日 - 9:00PM
ビジネスワイヤ(英語)
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) (the “Company” or
“Novo”), pioneering a holistic approach to patient-first health and
wellness through a multidisciplinary healthcare ecosystem of
services and product innovation, announced today its wholly owned
subsidiary, Novo Healthnet Limited (“NHL”), and EK-Tech Solutions
Inc. (“EK-Tech”) have established a joint venture company,
MiTelemed+ Inc., to operate, support, and expand access and
functionality of EK-Tech’s enhanced proprietary Telehealth platform
(“iTelemed”).
MiTelemed+, through the iTelemed platform, allows Novo to offer
the patient and the practitioner a sophisticated and enhanced
telehealth interaction. Through the interface of sophisticated
peripheral based diagnostic tools operated by skilled support
workers in the patient’s remote location, the practitioner’s
ability and comfort to provide a uniquely comprehensive evaluation,
diagnosis, and treatment solution is dramatically elevated.
Robert Mattacchione, Novo’s Chairman and CEO, stated, “The
pandemic has taught both patients and healthcare providers the
viability, importance, and benefits of telemedicine technology for
non-catastrophic primary care. To date, telehealth technology usage
is one dimensional and limiting in comfort for practitioners to
provide in-depth diagnosis and treatment solutions. Through our JV
with EK-Tech, MiTelemed+ offers the next generation of telehealth
technology capability. Beyond the patient’s laptop or desktop, the
iTelemed platform will interface with Novo’s mobile application,
NovoConnect, to provide patients and practitioners with an
additional platform to administer patients remotely and creating
virtual visits that are intended to be as real and as effective as
a physical visit.”
EK-Tech is contributing all intellectual property, source code,
and core data of the iTelemed platform. Additionally, MiTelemed+ is
contracted with EK-Tech to operate, maintain, support, provide
software hosting, and for further development of iTelemed’s
capabilities. NHL is responsible for global commercialization as
well as fulfilling all administrative functions for the JV. The net
profits and net losses of the JV will be split 50/50 between NHL
and EK-Tech.
Telemedicine is transforming traditional approaches to
healthcare by providing ease of access and reduced costs for
patients, particularly in areas with limited access to both
clinicians and medically licensed providers. In a post-pandemic
global environment, telemedicine through virtual technology is
rapidly being adopted by clinicians, medical licensed providers,
and the patient.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of services and product innovation. Novo
offers an essential and differentiated solution to deliver, or
intend to deliver, these services and products through the
integration of medical technology, advanced therapeutics, and
rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity offers an
essential solution to the fundamental transformation of healthcare
delivery. Specific to non-critical care, ongoing advancements in
both medical technology and inter-connectivity are allowing for a
shift of the patient/practitioner relationship to the patient’s
home and away from on-site visits to primary medical centers with
mass-services. This acceleration of “ease-of-access” in the
patient/practitioner interaction for non-critical care diagnosis
and subsequent treatment minimizes the degradation of non-critical
health conditions to critical conditions as well as allowing for
more cost-effective healthcare distribution.
Novo’s decentralized healthcare business model is centered on
three primary pillars to best support the transformation of
non-catastrophic healthcare delivery to patients and consumers. The
first pillar is building a foundation of traditional hands-on
healthcare delivery, through small and micro footprint sized clinic
facilities, within a significant service delivery network. The
second pillar is the development, integration, and deployment of
sophisticated technology, through interconnectivity, which expands
the reach of healthcare related service, beyond the traditional
clinic location, to geographic areas not readily providing advanced
healthcare service to date, including the patient’s home. The third
pillar is the development and distribution of effective wellness
product solutions allowing for the customization of patient
preventative care remedies and ultimately a healthier population.
Additionally, Novo’s science first approach to product innovation
further emphasizes Novo’s mandate to create and provide
over-the-counter preventative and maintenance care solutions.
Innovation in science as represented by proprietary technology
assures Novo of continued cutting edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on NHL,
please visit www.novohealthnet.com.
Twitter: https://twitter.com/novointegrated LinkedIn:
https://www.linkedin.com/company/60376520/admin/ Facebook:
https://www.facebook.com/novointegrated/ Instagram:
https://www.instagram.com/novointegrated/ YouTube:
https://www.youtube.com/channel/UCy3wpEIfQwwaf0BZ-34OKwQ
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211014005268/en/
Chris David, COO-President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 6 2024 まで 7 2024
Novo Integrated Sciences (NASDAQ:NVOS)
過去 株価チャート
から 7 2023 まで 7 2024